Peer-reviewedCC BYEinstein (Sao Paulo, Brazil)19 Oct 2026

Differences in the clinical profile between isolated lupus anticoagulant and triplepositive antiphospholipid antibody profiles in primary antiphospholipid syndrome.

Bruno Verza Azevedo¹
Flavio Signorelli²
Gustavo Guimarães Moreira Balbi³
Danieli Castro Oliveira Andrade¹

¹Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
²Rheumatology Service, Hospital Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
³Rheumatology Service, Hospital Universitário, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.

Abstract

Objective

To compare the clinical phenotype of patients with primary antiphospholipid syndrome who have isolated lupus anticoagulant positivity versus those with triple positivity.Methods

This cross-sectional study included two cohorts from two tertiary centers in Brazil comprising patients diagnosed with primary antiphospholipid syndrome.Results

Of 313 patients, 135 were selected and divided into two groups. A total of 99 had isolated lupus anticoagulant positivity and 36 had triple positivity. Most participants were female (58.5%) and White (61.5%), with a mean age of 50.1±12.0 years and a median disease duration of 16 (12-22) years. Both groups showed similar rates of thrombosis (93.9% in the lupus anticoagulant group versus 100% in the triple positivity group, p=0.131) and obstetric events (55.8% versus 60.0%, p=0.754). Microthrombotic and non-thrombotic event rates were also comparable. Hydroxychloroquine use was higher in the triple-positive group (36.1%) than in the lupus anticoagulant group (15.2%, p=0.008).Conclusion

No more severe phenotype was observed in patients with triple positivity compared with those with isolated lupus anticoagulant positivity. The mixed ancestry and demographic composition of the Brazilian population may explain differences compared with more homogeneous populations.

Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
Nozomu Ishikawa, Naoto Yamamoto, Tatsuro Yata +9
Annals of vascular diseases27 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
Clinical decision support tool evaluation: Correction of direct oral anticoagulant dosing errors by clinical pharmacists and physicians
Anish Saraswat, Shawna N. Smith, Michael P. Dorsch +5
Research and Practice in Thrombosis and Haemostasis1 Aug 2026Peer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
Carmine Siniscalchi, Alessandro Perrella, Ugo Trama +3
Frontiers in pharmacology30 Sep 2026Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCCrossref
Optimization of direct oral anticoagulant prescribing in primary care: a pharmacotherapeutic review in real-world clinical practice and therapeutic efficiency
Núria Gotanegra Guzmán, Marta Turu Pedrola, Montserrat Viñas-Bastart +5
Frontiers in Pharmacology14 Oct 2026Peer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMCPMC
CO100 | ANTIPHOSPHATIDYLSERINE–PROTHROMBIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME: CLINICAL ASSOCIATIONS AND DIAGNOSTIC GAPS MAPPED BY A SCOPING REVIEW
Ariela Hoxha
Bleeding, Thrombosis and Vascular Biology26 Oct 2026Peer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ

Cite

BibTeX RIS

BibTeX

@article{azevedo2026differences,
  title = {{Differences in the clinical profile between isolated lupus anticoagulant and triplepositive antiphospholipid antibody profiles in primary antiphospholipid syndrome.}},
  author = {Bruno Verza Azevedo and Flavio Signorelli and Gustavo Guimarães Moreira Balbi and Danieli Castro Oliveira Andrade},
  journal = {Einstein (Sao Paulo, Brazil)},
  year = {2026},
  month = oct,
  doi = {10.31744/einstein_journal/2026ao1654},
  url = {https://europepmc.org/article/MED/42912010},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Differences in the clinical profile between isolated lupus anticoagulant and triplepositive antiphospholipid antibody profiles in primary antiphospholipid syndrome.
AU  - Bruno Verza Azevedo
AU  - Flavio Signorelli
AU  - Gustavo Guimarães Moreira Balbi
AU  - Danieli Castro Oliveira Andrade
PY  - 2026
DA  - 2026/10/19
JO  - Einstein (Sao Paulo, Brazil)
DO  - 10.31744/einstein_journal/2026ao1654
UR  - https://europepmc.org/article/MED/42912010
AB  - Objective  To compare the clinical phenotype of patients with primary antiphospholipid syndrome who have isolated lupus anticoagulant positivity versus those with triple positivity.Methods  This cross-sectional study included two cohorts from two tertiary centers in Brazil comprising patients diagnosed with primary antiphospholipid syndrome.Results  Of 313 patients, 135 were selected and divided into two groups. A total of 99 had isolated lupus anticoagulant positivity and 36 had triple positivity. Most participants were female (58.5%) and White (61.5%), with a mean age of 50.1±12.0 years and a median disease duration of 16 (12-22) years. Both groups showed similar rates of thrombosis (93.9% in the lupus anticoagulant group versus 100% in the triple positivity group, p=0.131) and obstetric events (55.8% versus 60.0%, p=0.754). Microthrombotic and non-thrombotic event rates were also comparable. Hydroxychloroquine use was higher in the triple-positive group (36.1%) than in the lupus anticoagulant group (15.2%, p=0.008).Conclusion  No more severe phenotype was observed in patients with triple positivity compared with those with isolated lupus anticoagulant positivity. The mixed ancestry and demographic composition of the Brazilian population may explain differences compared with more homogeneous populations.
SN  - 1679-4508
SN  - 2317-6385
ER  -

Abstract

Related

Cite